Raynaud's Phenomenon Support Protocol
Primary Stack
Core supplements with strongest evidenceImproves blood flow; reduces blood viscosity; anti-inflammatory
Supporting Studies (1)
Improves peripheral circulation; may reduce attack frequency
Supporting Studies (1)
Supporting Stack
Additional supplements for enhanced resultsNitric oxide precursor; supports vasodilation
Supporting Studies (1)
GLA supports prostaglandin production; may improve circulation
Supporting Studies (1)
Antioxidant; may improve blood flow
Supporting Studies (1)
How This Protocol Works
Simple Explanation
Raynaud's phenomenon is a condition where blood vessels in the fingers and toes temporarily narrow in response to cold or stress, causing them to turn white, then blue, then red as blood flow returns.
TYPES:
TYPICAL ATTACK:
1. Fingers/toes turn white (vasospasm - no blood flow)
2. May turn blue (deoxygenation)
3. Turn red and throb as blood returns
4. May feel numb, cold, or painful
TRIGGERS:
PREVENTION:
MEDICAL TREATMENTS:
WHEN TO SEE A DOCTOR:
* Omega-3s and ginkgo may improve circulation.
* L-arginine supports blood vessel dilation.
* Lifestyle measures are essential.
Expected timeline: Supplements may reduce attack frequency within weeks to months. Lifestyle modifications often provide immediate benefit.
Clinical Perspective
Raynaud's Phenomenon: Episodic digital vasospasm. Primary (idiopathic): 80-90%, typically women <30, symmetric, benign. Secondary: connective tissue disease (scleroderma most common), medications, occupational. Distinguish by nailfold capillaroscopy, ANA, autoantibodies.
Treatment: Primary - lifestyle modification often sufficient (avoid cold, quit smoking). Calcium channel blockers (nifedipine) first-line pharmacotherapy. Secondary may need more aggressive treatment including prostacyclins. Supplements: omega-3, ginkgo have some evidence; L-arginine theoretical benefit. Red flags suggesting secondary: asymmetric, onset >30, severe attacks, digital ulcers - requires workup.
* Omega-3 (B-grade): Blood flow. Systematic review: (PMID: 27840029). 3-4g EPA+DHA daily.
* Ginkgo Biloba (B-grade): Peripheral circulation. Clinical trials: (PMID: 23888327). 120-240mg daily.
* L-Arginine (C-grade): NO precursor. Review: (PMID: 23999798). 3-6g daily.
* Evening Primrose Oil (C-grade): GLA prostaglandins. Clinical studies: (PMID: 23075608). 3-6g daily.
* Vitamin E (C-grade): Antioxidant. Review: (PMID: 23075608). 400-800 IU daily.
Assessment targets: Attack frequency and severity, digital ulcer prevention, quality of life.
Protocol notes: Nailfold capillaroscopy: abnormal in secondary; helps predict which primary may evolve to CTD. ANA: check in all new patients. Scleroderma: most common CTD association; can be first sign. Digital ulcers: require aggressive treatment; consider prostacyclins, bosentan. Medications to avoid: beta-blockers, ergots, stimulants. Smoking: absolute contraindication. Biofeedback: some evidence for primary. Calcium channel blockers: nifedipine XL 30-90mg; amlodipine alternative. Sildenafil: for severe refractory; 20mg TID. Topical nitrates: nitroglycerin patches to affected digits. Botox: emerging treatment for refractory. Cold exposure: whole body warming more effective than just warming hands.